FR22C1034I2 - FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS - Google Patents
FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERSInfo
- Publication number
- FR22C1034I2 FR22C1034I2 FR22C1034C FR22C1034C FR22C1034I2 FR 22C1034 I2 FR22C1034 I2 FR 22C1034I2 FR 22C1034 C FR22C1034 C FR 22C1034C FR 22C1034 C FR22C1034 C FR 22C1034C FR 22C1034 I2 FR22C1034 I2 FR 22C1034I2
- Authority
- FR
- France
- Prior art keywords
- treatment
- proliferative disorders
- hematopoietic cancers
- fixed drug
- drug ratios
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90177207P | 2007-02-16 | 2007-02-16 | |
US96519607P | 2007-08-17 | 2007-08-17 | |
EP08730048.9A EP2120568B1 (en) | 2007-02-16 | 2008-02-15 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
PCT/US2008/054168 WO2008101214A2 (en) | 2007-02-16 | 2008-02-15 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
FR22C1034I1 FR22C1034I1 (en) | 2022-09-09 |
FR22C1034I2 true FR22C1034I2 (en) | 2023-06-30 |
Family
ID=39690832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR22C1034C Active FR22C1034I2 (en) | 2007-02-16 | 2022-07-05 | FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS |
Country Status (20)
Country | Link |
---|---|
US (2) | US8092828B2 (en) |
EP (3) | EP3300601B1 (en) |
JP (1) | JP5314600B2 (en) |
KR (2) | KR20150038752A (en) |
CN (1) | CN105998046A (en) |
AU (1) | AU2008216083B2 (en) |
CA (1) | CA2678332C (en) |
CY (1) | CY1119631T1 (en) |
DK (2) | DK2120568T3 (en) |
ES (2) | ES2909903T3 (en) |
FR (1) | FR22C1034I2 (en) |
HK (1) | HK1253378A1 (en) |
HR (1) | HRP20220428T3 (en) |
HU (2) | HUE058334T2 (en) |
NL (1) | NL301185I2 (en) |
NO (1) | NO2120568T3 (en) |
PL (2) | PL2120568T3 (en) |
PT (2) | PT3300601T (en) |
SI (1) | SI3300601T1 (en) |
WO (1) | WO2008101214A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100075937A1 (en) * | 2008-09-24 | 2010-03-25 | Hollis-Eden Pharmaceuticals, Inc. | Patient populations and treatment methods |
KR102284689B1 (en) * | 2011-10-21 | 2021-08-02 | 셀라토 파마슈티칼즈, 인코포레이티드 | Lyophilized liposomes |
US20140154304A1 (en) * | 2012-11-30 | 2014-06-05 | Boehringer Ingelheim International Gmbh | Combination therapy with volasertib |
WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
EP3373919A4 (en) | 2015-11-11 | 2019-06-19 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
WO2019023873A1 (en) * | 2017-07-31 | 2019-02-07 | 江苏竞诺择生物医药科技有限公司 | Nano-lipid microparticle composition and pharmaceutical composition for treating hematopoietic system proliferative diseases |
MX2021003527A (en) * | 2018-09-25 | 2021-05-27 | Celator Pharmaceuticals Inc | Low-intensity treatment of hematological disorders. |
CN113473980A (en) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | Gamma-hydroxybutyrate compositions with improved pharmacokinetics in fed state |
US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
ZA200503653B (en) * | 2002-11-06 | 2006-08-30 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
BR0215935A (en) * | 2002-11-06 | 2005-08-09 | Wyeth Corp | Combination therapy for treatment of acute leukemia and myelodysplastic syndrome |
PT1744764E (en) | 2004-04-22 | 2012-08-30 | Celator Pharmaceuticals Inc | Liposomal formulations of anthracycline agents and cytidine analogs |
SE0402025D0 (en) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
-
2008
- 2008-02-15 PL PL08730048T patent/PL2120568T3/en unknown
- 2008-02-15 PT PT172004988T patent/PT3300601T/en unknown
- 2008-02-15 NO NO08730048A patent/NO2120568T3/no unknown
- 2008-02-15 KR KR20157007810A patent/KR20150038752A/en active Search and Examination
- 2008-02-15 PT PT87300489T patent/PT2120568T/en unknown
- 2008-02-15 HU HUE17200498A patent/HUE058334T2/en unknown
- 2008-02-15 EP EP17200498.8A patent/EP3300601B1/en active Active
- 2008-02-15 EP EP22150734.6A patent/EP4046640A1/en active Pending
- 2008-02-15 JP JP2009550160A patent/JP5314600B2/en active Active
- 2008-02-15 CN CN201610324431.2A patent/CN105998046A/en active Pending
- 2008-02-15 ES ES17200498T patent/ES2909903T3/en active Active
- 2008-02-15 CA CA2678332A patent/CA2678332C/en active Active
- 2008-02-15 US US12/032,583 patent/US8092828B2/en active Active
- 2008-02-15 DK DK08730048.9T patent/DK2120568T3/en active
- 2008-02-15 US US12/526,930 patent/US20100303895A1/en not_active Abandoned
- 2008-02-15 PL PL17200498T patent/PL3300601T3/en unknown
- 2008-02-15 DK DK17200498.8T patent/DK3300601T3/en active
- 2008-02-15 HR HRP20220428TT patent/HRP20220428T3/en unknown
- 2008-02-15 KR KR1020097019393A patent/KR20100014441A/en active Application Filing
- 2008-02-15 AU AU2008216083A patent/AU2008216083B2/en active Active
- 2008-02-15 SI SI200832194T patent/SI3300601T1/en unknown
- 2008-02-15 WO PCT/US2008/054168 patent/WO2008101214A2/en active Application Filing
- 2008-02-15 EP EP08730048.9A patent/EP2120568B1/en not_active Revoked
- 2008-02-15 ES ES08730048.9T patent/ES2650167T3/en active Active
-
2017
- 2017-11-29 CY CY20171101251T patent/CY1119631T1/en unknown
-
2018
- 2018-10-03 HK HK18112675.7A patent/HK1253378A1/en unknown
-
2022
- 2022-07-05 NL NL301185C patent/NL301185I2/en unknown
- 2022-07-05 FR FR22C1034C patent/FR22C1034I2/en active Active
- 2022-07-07 HU HUS2200032C patent/HUS2200032I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR22C1034I2 (en) | FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | |
FR2925339B1 (en) | DRUG FOR THE TREATMENT OF PANCREATIC CANCER | |
FR2948016B1 (en) | ORTHESIS FOR THE TREATMENT OF RHIZARTHROSIS | |
HK1163119A1 (en) | Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4 | |
FR2929946B1 (en) | NOVEL ANTI-CD151 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER | |
FR2907011B1 (en) | USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS | |
IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
EP2205236A4 (en) | Novel agents for treatment of ailments and dysfunctions | |
FR2915102B1 (en) | USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER | |
FR2948687B1 (en) | USE OF MICROARN FOR THE TREATMENT OF CHRONIC RESPIRATORY DISEASES | |
IL217839A (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
MA44700A (en) | COMBINATION OF ANTI-IL-10 ANTIBODY AND CPG-C OLIGONUCLEOTIDE FOR THE TREATMENT OF CANCER | |
FR2917947B1 (en) | PHYTOSANITARY COMPOSITION FOR THE PREVENTIVE AND CURATIVE TREATMENT OF MILDIOU | |
FR2902320B1 (en) | USE OF BUTYLATED HYDROXYANISOLE FOR THE TREATMENT OF CANITIA | |
FR2910324B1 (en) | NEW MEDICINE FOR THE TREATMENT OF GASTRIC CANCER | |
FR2910813B1 (en) | NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA | |
IL193943A0 (en) | The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain | |
FR2924593B1 (en) | BONE PLATE FOR THE TREATMENT OF THE LOWER END OF THE CUBITUS | |
PT2344166E (en) | Pharmaceutical composition for the treatment of gastrointestinal irritation disorders | |
FR2916345B1 (en) | DEVICE FOR THE TREATMENT OF THE REAGONMENT OF THE EYE | |
FR2937550B1 (en) | USE OF CITRULLINE FOR THE TREATMENT AND PREVENTION OF ISCHEMIA-REPERFUSION SYNDROME | |
FR2953412B1 (en) | MEDICAMENT FOR THE TREATMENT OF GASTROINTESTINAL ULCERS | |
IL193944A0 (en) | The use beta-aminoalcohols for the treatment of inflammatory disorders and pain | |
FR2921061B1 (en) | INDOLONE DERIVATIVES FOR THE TREATMENT OF MALARIA | |
FR2902321B1 (en) | USE OF CURCUMIN FOR THE TREATMENT OF CANITIA |